glp-1 and dementia Frontiers GLP-1 receptor agonists reduce dementia

Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M

Retatrutide works through simultaneous activation of three metabolic receptors: GLP-1 (which reduces appetite and improves insulin secretion), GIP (which enhances insulin sensitivity and influences fat storage), and glucagon (which increases energy expenditure and promotes hepatic fat oxidation)

The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising

This probiotic blend is fueled by good dietary fiber

Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ